MétaCan
Menu
Back to cohort
Record W4410154857 · doi:10.1186/s12879-025-11068-1

Non-inferiority stepped wedge cluster randomized controlled trial on all-oral shorter regimens for rifampicin resistant/multidrug-resistant TB in Pakistan – a study protocol

2025· article· en· W4410154857 on OpenAlexaff
Nida Tabassum Khan, Muhammad Ahmar Khan, Naila Muzaffar, Ahmad Izuanuddin Ismail, Abdul Ghafoor, Jonathon R. Campbell, Gwenaëlle Le Coroller, Corinne Merle, Muhammad Amir Khan

Bibliographic record

VenueBMC Infectious Diseases · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
TopicAntibiotic Use and Resistance
Canadian institutionsMcGill UniversityMcGill University Health Centre
FundersUNICEFTDRWorld Health Organization
KeywordsMedicineRifampicinMedical microbiologyRandomized controlled trialInternal medicineParasitologyProtocol (science)TuberculosisVirologyAlternative medicinePathology

Abstract

fetched live from OpenAlex

INTRODUCTION: Pakistan has one of the largest burdens of rifampicin-resistant/ multidrug-resistant TB according to the global estimates. Novel all oral treatment regimens containing new antibiotics with reduced treatment duration are available. World Health Organization guidelines recommend the use of shorter all-oral regimens under operational research. To guide recommendations, we will compare two all-oral, short (≤ 11 months) regimens for the outcomes of efficacy, safety, cost, and health-related quality of life under programmatic conditions in Pakistan. METHODS: This is a stepped wedge, cluster randomized controlled trial with economic evaluation and health related quality of life sub-studies. Modified all-oral 9-month regimen will be sequentially rolled-out compared with the standard all-oral 11-month regimen at 12 sites in Punjab, Islamabad and Azad Jammu and Kashmir region, Pakistan. A total of 400 eligible participants will be enrolled in both study arms. The primary outcome is difference in efficacy as measured by the proportion of patients with treatment success without recurrence at 12 months after the end of treatment between regimens using a non-inferiority design with a margin of 12%. The intention to treat analysis principle will be employed and a marginal mean model with Poisson generalized estimation equations, and a log-link will be used to assess the relative risk. The economic evaluation will be carried out from the healthcare providers perspective; linear mixed models will be used to estimate differences in costs between arms. Health related quality of life will be measured with the EQ-5D-3L quality of life questionnaire at four time points during the study period. The impact will be assessed by calculating the changes for each participant between time points. Ethical approval for this study has been obtained from national bioethics committee, Pakistan (Ref: No.4-87/NBC-491/20/48). DISCUSSION: The study's findings will be disseminated to physicians, program implementers, scientific audiences, and policymakers on both a national and international level via reports, presentations, and scientific publications. TRIAL REGISTRATION: ISRCTN registry. ISRCTN17334530, 'retrospectively registered' on 8th February 2021. 'Clinical trial number: not applicable.'

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.010
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.038
Threshold uncertainty score0.128

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0120.010
Meta-epidemiology (narrow)0.0040.001
Meta-epidemiology (broad)0.0080.004
Bibliometrics0.0010.002
Science and technology studies0.0010.002
Scholarly communication0.0030.002
Open science0.0030.001
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0380.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.339
Teacher spread0.327 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBMC Infectious DiseasesSame topicAntibiotic Use and ResistanceFrench-language works237,207